IDH1 and glioblastoma: Our data also showed that patients with astrocytic tumours harbouring IDH1 mutations had a significantly longer PFS than those with wildtype IDH1. Furthermore, Hartmann et al. 11 found that patients with IDH1-mutant glioblastoma have a more favourable PFS than those with IDH1-WT AA.